- Home
- PRGS vs LQDA Comparison
PRGS vs LQDA Comparison
Compare PRGS & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGS
- LQDA
- Stock Information
- Founded
- PRGS 1981
- LQDA 2004
- Country
- PRGS United States
- LQDA United States
- Employees
- PRGS N/A
- LQDA N/A
- Industry
- PRGS Computer Software: Prepackaged Software
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- PRGS Technology
- LQDA Health Care
- Exchange
- PRGS Nasdaq
- LQDA Nasdaq
- Market Cap
- PRGS 1.8B
- LQDA 1.9B
- IPO Year
- PRGS 1991
- LQDA 2018
- Fundamental
- Price
- PRGS $46.86
- LQDA $24.22
- Analyst Decision
- PRGS Buy
- LQDA Strong Buy
- Analyst Count
- PRGS 6
- LQDA 9
- Target Price
- PRGS $70.00
- LQDA $32.67
- AVG Volume (30 Days)
- PRGS 1.2M
- LQDA 2.9M
- Earning Date
- PRGS 09-29-2025
- LQDA 11-12-2025
- Dividend Yield
- PRGS N/A
- LQDA N/A
- EPS Growth
- PRGS N/A
- LQDA N/A
- EPS
- PRGS 1.09
- LQDA N/A
- Revenue
- PRGS $940,126,000.00
- LQDA $19,322,000.00
- Revenue This Year
- PRGS $30.95
- LQDA $405.58
- Revenue Next Year
- PRGS $1.77
- LQDA $373.93
- P/E Ratio
- PRGS $42.84
- LQDA N/A
- Revenue Growth
- PRGS 31.41
- LQDA 30.20
- 52 Week Low
- PRGS $40.29
- LQDA $9.71
- 52 Week High
- PRGS $70.56
- LQDA $29.94
- Technical
- Relative Strength Index (RSI)
- PRGS 61.38
- LQDA 51.93
- Support Level
- PRGS $45.03
- LQDA $21.35
- Resistance Level
- PRGS $47.37
- LQDA $23.33
- Average True Range (ATR)
- PRGS 1.59
- LQDA 1.19
- MACD
- PRGS 0.76
- LQDA -0.07
- Stochastic Oscillator
- PRGS 93.07
- LQDA 69.54
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.